ARDT240920P17500
- 0.80
- 0.000.00%
Ardent Health Partners Newsroom
Stephens & Co. Reiterates Overweight on Ardent Health Partners, Maintains $24 Price Target
Ardent Health Partners Analyst Ratings
Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ardent Health Partners, Inc. (ARDT), AdaptHealth (AHCO) and Ramsay Health Care (OtherRMSYF)
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $22
Loop Capital Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Raises Target Price to $21
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Announces Target Price $22
Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27
A Quick Look at Today's Ratings for Ardent Health Partners(ARDT.US), With a Forecast Between $21 to $27
Buy Rating Affirmed: Ardent Health Partners' Impressive Performance and Growth Potential
Analysts Are Bullish on These Healthcare Stocks: Biote (BTMD), Ardent Health Partners, Inc. (ARDT)
Ardent Health Partners Analyst Ratings
Stephens & Co. Reiterates Overweight on Ardent Health Partners, Maintains $24 Price Target
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Encompass Health (EHC) and Ardent Health Partners, Inc. (ARDT)
Loop Capital Initiates Ardent Health Partners(ARDT.US) With Buy Rating, Announces Target Price $18
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating
Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27
B of A Securities Initiates Coverage On Ardent Health Partners With Buy Rating, Announces Price Target of $22
RBC Initiates Ardent Health Partners at Outperform With $23 Price Target
Ardent Health Partners, Inc.: Buy Rating With Strong Revenue and EBITDA Growth Potential